Stock IMP A SDB IMPLANTICA AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Implantica AG

Equities

IMP A SDB

SE0014855029

Market Closed - Nasdaq Stockholm
Other stock markets
 11:24:26 2024-05-28 am EDT 		5-day change 1st Jan Change
28.4 SEK +0.35% Intraday chart for Implantica AG 0.00% +18.83%
May. 15 Transcript : Implantica AG, Q1 2024 Earnings Call, May 15, 2024
May. 15 Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
IMPLANTICA AG Stock Implantica AG
+18.83% 755M -
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+75.56% 12.55B
B-
PENUMBRA, INC. Stock Penumbra, Inc.
-23.35% 7.51B
C+
MASIMO CORPORATION Stock Masimo Corporation
+8.51% 6.74B
C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+14.95% 5.48B
D+
GETINGE AB Stock Getinge AB
-14.65% 4.93B
B
APT MEDICAL INC. Stock APT Medical Inc.
+30.59% 4.71B -
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-25.52% 3.83B
B-
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-22.61% 2.9B
C
NOVOCURE LIMITED Stock NovoCure Limited
+49.50% 2.49B
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IMP A SDB Stock
  4. Ratings Implantica AG